Welcome to the 5th Annual Gene Therapy Analytical Development Summit 2023
Develop, Validate & Implement Robust Analytical Tools to Guarantee Safety, Efficacy, Quality, & Consistency of Gene Therapy Products
As the gene therapy landscape continues to evolve, analytical technologies and capabilities are developing just as rapidly.
With increased scrutiny from regulators, more products entering later-stage development, and continued focus on ensuring therapeutic safety, it is key for analytical scientists to come together at a dedicated forum to benchmark against other gene therapy companies, connect with companies that could outsource some of their work, and keep up to date with and implement the cutting-edge analytical methods developments.
In this context, the 5th Annual Gene Therapy Analytical Development Summit returned as the leading industry-focused forum exploring how the latest analytical methods are being developed and implemented to guarantee the quality, consistency, safety, and efficacy of gene therapy products.
With the largest and most comprehensive program to date, expert presentations spanned bioassays, molecular biology, physicochemical properties, quality, process development and, for the very first time, dedicated sessions to CMC and regulation at the brand-new regulatory focus day.
This was your must-attend meeting to collaborate ideas, success, and challenges to capitalize on the technological advances in analytical development and deliver the potential of gene therapies to bring safer, efficacious therapies to patients more quickly and effectively.
“This is one of the best conferences I have ever attended as a scientist and vendor. The title is on point and extremely relevant. The audience was highly competent, motivated, and curious”
2022 Attendee, Malvern Panalytical
2023 World-Class Speaker Faculty Includes:
Director, Research & Development
Research Associate, Department of Chemistry & Biochemistry
University of Lethbridge
Associate Director, Group Leader
Associate Director, Analytical & Biophysical Development
Senior Director, Analytical Development, Cell & Gene Therapy
Quality Evaluator, Cells, Gene Therapies and Radiopharmaceuticals Division
BridgeBio Gene Therapy
Lead Scientist, Analytical Program Development
Chief Technology Officer
Previously Attending Companies Include:
“GTAD was my favorite conference I attended all last year by far! It strikes a great balance between broadness and the topics being narrow enough that all attendees are very engaged. As an attendee this means all the talks are interesting and relevant to my work. As a speaker this means an engaged audience with insightful questions and valuable feedback.”
2022 Attendee, Sanofi